Soligenix, Inc. — Form 10-Q Summary
Business context and reporting period. This unaudited report covers the quarter and six months ended June 30, 2011. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and BioDefense segments. Revenue was principally from NIH grants; its principal clinical program was orBec for acute gastrointestinal graft-versus-host disease (GI GVHD).
Financial performance and position
| Metric | Three months ended June 30, 2011 | Six months ended June 30, 2011 |
|---|---|---|
| Revenue, principally grants | $405,820 | $1,213,825 |
| Gross profit (gross margin) | $56,309 (13.9%) | $310,277 (25.6%) |
| Operating expenses | $1,989,099 | $3,965,913 |
| Net loss | $1,931,317 | $3,651,728 |
| Net loss per share | $0.01 | $0.02 |
- Compared with 2010, quarterly revenue fell 9% and net loss increased 22%; six-month revenue rose 56% and net loss narrowed 2%. Management attributed six-month revenue growth to increased NIH grant activity. Quarterly R&D expense rose 22%, mainly from greater orBec Phase 3 trial activity.
- Six-month operating cash use was $3,506,317, versus $2,506,355 in 2010. Investing cash use was $112,398; financing provided $323,750, including $255,000 from Fusion Capital equity sales and $68,750 from option and warrant exercises. Cash declined $3,294,965 to $4,156,749.
- At June 30, current assets were $4,589,266, current liabilities $1,423,276, and working capital $3,165,990, down 48% from year-end 2010. Total assets were $5,852,909 and shareholders’ equity $4,429,633. The filing reports no interest-bearing debt.
- Common shares outstanding were 218,240,167 at June 30; 27.5 million options and 54.2 million warrants were outstanding. The filing reported 220,791,077 common shares outstanding as of August 9.
Material changes, outlook, and risks
- Subsequent licensing agreement: On July 28, 2011, Sigma-Tau’s orBec license was expanded to Europe. Soligenix received a $5 million upfront payment after quarter-end, with up to $11 million in additional European milestone payments, 40% royalties on European net sales, and commercialization costs covered by Sigma-Tau. Total potential milestone payments under the agreement, including the existing North American agreement, could reach $20 million. A $2 million milestone is tied to successful completion of the confirmatory Phase 3 trial.
- Under a July 26 amendment to its license agreement, Soligenix paid Dr. McDonald $612,500 in cash and issued 1,337,793 shares valued at $400,000 in connection with the Sigma-Tau amendment; a further $400,000 cash payment is due upon European Medicines Agency approval of orBec.
- Management expected cash to fund working capital and capital expenditures into the first quarter of 2013, based on cash on hand, timely milestone collections, the European license payment, grants, and potential Fusion Capital proceeds. This is a forward-looking estimate, not a guarantee. The company had about $8.4 million in active grant funding and about $7.4 million of remaining Fusion Capital capacity through October 2011; additional equity financing may be needed and is not assured.
- Management projected approximately $7.7 million of R&D spending over the next 12 months before grant reimbursements. The confirmatory orBec Phase 3 trial was expected to complete in the second half of 2011; SGX201 Phase 1/2 data and RiVax Phase 1B immunogenicity results were expected in 2011.
- Clinical and regulatory outcomes remain key risks. The prior pivotal orBec Phase 3 study missed its primary endpoint, and the FDA had previously requested additional clinical and other data. The ongoing confirmatory trial must succeed to support the next regulatory submission. The company also cited risks common to biotechnology businesses, including dependence on grant funding, financing availability, product development, FDA requirements, intellectual property, and potential litigation and product liability.
- Commitments included approximately $505,000 for Phase 3 trial data-capture services. Licensing arrangements may require future milestone or royalty payments if clinical or commercial milestones are achieved. Management reported disclosure controls were effective and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the final enrollment, completion timing, endpoint results, and regulatory implications of the orBec confirmatory Phase 3 trial.
- Track use of the $5 million European upfront payment, the related licensor payments and share issuance, and whether Sigma-Tau milestones or royalties are ultimately earned.
- Assess cash burn against management’s runway estimate, grant availability, Fusion Capital capacity, and any additional financing or dilution.
- Verify expected 2011 SGX201 and RiVax data timing and results, as well as continued grant funding for BioDefense programs.
- Review the substantial outstanding options and warrants and the potential dilution from future equity issuance.